Answers are grounded in this paper and cite their sources.
Observational study shows abemaciclib is safe and effective in breast cancer patients, suggesting its positive impact.
In this largest real-world study of abemaciclib in China to date, abemaciclib was well tolerated with no new safety signals, and its effectiveness was consistent with prior trials, confirming its positive benefit-risk profile in real-world settings.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: